CAR-NK cell therapy targeting MSLN, EGFR, or HER2
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for CAR-NK cell therapy targeting MSLN, EGFR, or HER2, covering 2026-03-12 to 2026-03-12. Get the full timeline:
Most recent: Clinical Trial Update: Dual-Target CAR-NK Cells Directed Against MSLN, EGFR, or HER2 in Advanced NSCLC [Phase 1, Phase 2]